165 results
425
EX-10.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit
425
EX-99.2
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
for success of P2B001, the presentation of financial information in U.S. GAAP, completion of a PCAOB audit of U.S. GAAP financials, as well as other risks
425
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
of financial information in U.S. GAAP, completion of a PCAOB audit of U.S. GAAP financials, as well as other risks that will be set forth in more detail
425
EX-2.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
the following meanings:
“Action” means any action, claim, suit, audit, arbitration or legal, judicial or administrative proceeding (whether at law … within the six (6) years prior to the date hereof been the subject of an examination, investigation or audit by a Governmental Authority or the subject
8-K
EX-2.1
1sf8tj 1yj
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
8-K
EX-10.1
zfc80g
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
8-K
8de0u8u7
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
8-K
EX-99.2
tamo7o3o
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
424B3
0f6 ps2n5
15 Jul 24
Prospectus supplement
5:17pm
NT 10-K
6qy1meakz73a
1 Apr 24
Notice of late annual filing
4:30pm